BRPI0820912A2 - Coadministração de uma agente ligado a um peptídeo de internalização com um agente anti- inflamatório - Google Patents
Coadministração de uma agente ligado a um peptídeo de internalização com um agente anti- inflamatórioInfo
- Publication number
- BRPI0820912A2 BRPI0820912A2 BRPI0820912A BRPI0820912A BRPI0820912A2 BR PI0820912 A2 BRPI0820912 A2 BR PI0820912A2 BR PI0820912 A BRPI0820912 A BR PI0820912A BR PI0820912 A BRPI0820912 A BR PI0820912A BR PI0820912 A2 BRPI0820912 A2 BR PI0820912A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- coadministration
- internalization peptide
- linked
- inflammatory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99267807P | 2007-12-05 | 2007-12-05 | |
| US60/992,678 | 2007-12-05 | ||
| PCT/US2008/085280 WO2009076105A2 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0820912A2 true BRPI0820912A2 (pt) | 2018-07-17 |
| BRPI0820912B1 BRPI0820912B1 (pt) | 2022-05-24 |
Family
ID=40756064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0820912-0A BRPI0820912B1 (pt) | 2007-12-05 | 2008-12-02 | Uso de um agente farmacológico ligado a um peptídeo tat, uso de um inibidor de degranulação de mastócito ou anti-histamínico e kit compreendendo um agente farmacológico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8080518B2 (pt) |
| EP (1) | EP2229185B8 (pt) |
| JP (1) | JP5520230B2 (pt) |
| CN (1) | CN101970011B (pt) |
| AU (1) | AU2008335490B2 (pt) |
| BR (1) | BRPI0820912B1 (pt) |
| DK (1) | DK2229185T3 (pt) |
| ES (1) | ES2555524T3 (pt) |
| HR (1) | HRP20151312T1 (pt) |
| HU (1) | HUE027216T2 (pt) |
| PL (1) | PL2229185T3 (pt) |
| PT (1) | PT2229185E (pt) |
| SI (1) | SI2229185T1 (pt) |
| WO (1) | WO2009076105A2 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| JP5746468B2 (ja) * | 2006-07-11 | 2015-07-08 | ノノ インコーポレイテッド | 発熱を伴う脳卒中を処置する方法および組成物 |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| CN102088990A (zh) * | 2008-05-16 | 2011-06-08 | 阿尔伯维塔公司 | 癫痫的治疗 |
| AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
| ES2847293T3 (es) | 2009-06-10 | 2021-08-02 | Nono Inc | Regímenes de tratamiento para el tratamiento de enfermedades neurológicas |
| WO2011038397A2 (en) * | 2009-09-28 | 2011-03-31 | Duke University | Peptide adjuvants, vaccines, and methods of use |
| WO2011126833A2 (en) * | 2010-03-29 | 2011-10-13 | Massachusetts Institute Of Technology | Anti-inflammatory factors |
| AU2011279703B2 (en) * | 2010-06-10 | 2016-07-07 | Indiana University Research And Technology Corporation | Materials and method for suppressing inflamatory and neuropathic pain |
| CA2807946C (en) * | 2010-08-12 | 2018-09-25 | Nono Inc. | Treatment of penetrative injury to the brain |
| KR102046830B1 (ko) * | 2011-05-13 | 2019-11-20 | 코벤하븐스 유니버시테트 | 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제 |
| DK3427748T3 (da) | 2011-06-24 | 2022-04-19 | Nono Inc | Kombinationsterapi mod iskæmi |
| WO2013148366A1 (en) | 2012-03-27 | 2013-10-03 | Duke Unversity | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| CN109106941A (zh) * | 2012-11-28 | 2019-01-01 | 诺诺公司 | Tat-nr2b9c的冻干制剂 |
| WO2014150350A1 (en) * | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| PL2946765T3 (pl) | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2016049280A1 (en) * | 2014-09-24 | 2016-03-31 | Memorial Sloan Kettering Cancer Center | mTORC1 MODULATION |
| BR112020006321A2 (pt) * | 2017-09-30 | 2020-11-17 | Biocells (Beijing) Biotech Co., Ltd. | composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034468A2 (en) * | 1998-12-11 | 2000-06-15 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| US6593292B1 (en) * | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) * | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| AU2002356511A1 (en) * | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| US20060276455A1 (en) * | 2003-02-13 | 2006-12-07 | Lindsberg Perttu J | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| WO2006029028A2 (en) * | 2004-09-02 | 2006-03-16 | Cognosci, Inc. | Improved apo e analogs and methods for their use |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| WO2009006611A1 (en) * | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| KR20170016031A (ko) * | 2007-07-26 | 2017-02-10 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
-
2008
- 2008-11-26 US US12/323,915 patent/US8080518B2/en active Active
- 2008-12-02 AU AU2008335490A patent/AU2008335490B2/en not_active Ceased
- 2008-12-02 BR BRPI0820912-0A patent/BRPI0820912B1/pt active IP Right Grant
- 2008-12-02 ES ES08859906.3T patent/ES2555524T3/es active Active
- 2008-12-02 PT PT88599063T patent/PT2229185E/pt unknown
- 2008-12-02 EP EP08859906.3A patent/EP2229185B8/en active Active
- 2008-12-02 DK DK08859906.3T patent/DK2229185T3/en active
- 2008-12-02 JP JP2010537016A patent/JP5520230B2/ja active Active
- 2008-12-02 PL PL08859906T patent/PL2229185T3/pl unknown
- 2008-12-02 SI SI200831555T patent/SI2229185T1/sl unknown
- 2008-12-02 WO PCT/US2008/085280 patent/WO2009076105A2/en active Application Filing
- 2008-12-02 CN CN2008801261196A patent/CN101970011B/zh active Active
- 2008-12-02 HU HUE08859906A patent/HUE027216T2/en unknown
-
2015
- 2015-12-02 HR HRP20151312TT patent/HRP20151312T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2229185E (pt) | 2016-01-26 |
| PL2229185T3 (pl) | 2016-03-31 |
| HRP20151312T1 (hr) | 2016-03-11 |
| CN101970011B (zh) | 2013-04-24 |
| HUE027216T2 (en) | 2016-08-29 |
| WO2009076105A2 (en) | 2009-06-18 |
| EP2229185A4 (en) | 2011-11-23 |
| BRPI0820912B1 (pt) | 2022-05-24 |
| JP5520230B2 (ja) | 2014-06-11 |
| ES2555524T3 (es) | 2016-01-04 |
| SI2229185T1 (sl) | 2016-02-29 |
| AU2008335490B2 (en) | 2013-08-22 |
| EP2229185A2 (en) | 2010-09-22 |
| CN101970011A (zh) | 2011-02-09 |
| AU2008335490A1 (en) | 2009-06-18 |
| US20090176713A1 (en) | 2009-07-09 |
| JP2011506328A (ja) | 2011-03-03 |
| EP2229185B8 (en) | 2016-12-21 |
| WO2009076105A3 (en) | 2010-01-07 |
| US8080518B2 (en) | 2011-12-20 |
| DK2229185T3 (en) | 2016-01-11 |
| EP2229185B1 (en) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820912A2 (pt) | Coadministração de uma agente ligado a um peptídeo de internalização com um agente anti- inflamatório | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| BRPI0905680A2 (pt) | "composição farmacêutica de uma composição farmacêutica" | |
| BRPI1013421A2 (pt) | composição parasticida tópica, e, uso de uma composição | |
| BRPI1005931A8 (pt) | associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica | |
| BRPI0821165A2 (pt) | Uso de uma composição | |
| DK2420223T3 (da) | Vandige farmaceutiske sammensætninger med borat-polyol-komplekser | |
| BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
| EP2440231A4 (en) | CO-ADMINISTRATION OF AN INTERNALIZATION PEPTIDE AGENT WITH ANTI-INFLAMMATORY | |
| BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
| BRPI0813139A2 (pt) | Peptídeo glp-1 com adição de uma cadeia oligossacarídea | |
| BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
| BRPI0913822A2 (pt) | forma farmacêutica oral e uso da forma farmacêutica | |
| BRPI1006666A2 (pt) | " composição farmacêutica e uso de uma composição farmacêutica" | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| BRPI0914793A2 (pt) | Composição, e, uso de uma composição | |
| BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
| BRPI0920355A2 (pt) | composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina | |
| BRPI0915427A2 (pt) | composição farmacêutica | |
| BRPI0916069A2 (pt) | "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição" | |
| BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
| BR112012014028A2 (pt) | uso de uma composição | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| DK2193795T3 (da) | Latanoprostholdig vandig farmaceutisk sammensætning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |